BENGALURU (Reuters) – Indian drugmaker Shilpa Medicare Ltd has the production capacity to make 100-200 million doses of a recombinant vaccine for COVID-19, a company executive told Reuters on Wednesday.
The company’s shares jumped as much as 9.2% on India’s National Stock Exchange following the news.
Reporting by Sachin Ravikumar in Bengaluru; Editing by Shounak Dasgupta
